Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Equity (2021 - 2025)

Historic Return on Equity for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 0.48%.

  • SAB Biotherapeutics' Return on Equity rose 6200.0% to 0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year increase of 6200.0%. This contributed to the annual value of 1.01% for FY2024, which is 500.0% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Return on Equity is 0.48%, which was up 6200.0% from 2.44% recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Return on Equity peaked at 0.15% during Q3 2021, and registered a low of 2.44% during Q2 2025.
  • For the 5-year period, SAB Biotherapeutics' Return on Equity averaged around 0.94%, with its median value being 0.82% (2024).
  • Examining YoY changes over the last 5 years, SAB Biotherapeutics' Return on Equity showed a top increase of 6200bps in 2025 and a maximum decrease of -16300bps in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Return on Equity (Quarter) stood at 0.47% in 2021, then plummeted by -30bps to 0.61% in 2022, then plummeted by -92bps to 1.16% in 2023, then rose by 11bps to 1.04% in 2024, then surged by 54bps to 0.48% in 2025.
  • Its Return on Equity stands at 0.48% for Q3 2025, versus 2.44% for Q2 2025 and 1.62% for Q1 2025.